🟢 Cerenome is trading 54.33% up — cause remains unclear

Cerenome is trading at $2.64, up +54.33%, with the cause of the November 3 move unclear.

• No clear company-specific catalyst for the sharp rise was identified in available coverage.
• Cerenome’s latest major announcement was October 29, when it completed enrollment in its Phase 2 ReSPECT-GBM trial; topline data are expected in mid-2027. This prior news is not a confirmed explanation for the move.
• Broader market signals were mixed, and available evidence does not establish market sentiment as the cause.